Lupin Pharmaceuticals Inc. is recalling 111,648 units of Duloxetine Delayed-Release Capsules USP (30 mg), a prescription medication used to treat depression and anxiety. The recall was initiated because the product failed to meet dissolution specifications during testing, which means the medication may not release properly in the body. Consumers who have these 30-count bottles should contact their healthcare provider or pharmacist for guidance regarding their treatment.
If a delayed-release medication fails to dissolve as intended, it may release the active ingredient too early or too late, potentially reducing the effectiveness of the drug or causing unexpected side effects.
Healthcare consultation and pharmacy refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.